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 Abstract 
Background— Electrical conduction from the cardiac sinoatrial node to the ventricles is critical for 
normal heart function. Genome-wide association studies (GWAS) have identified more than a dozen 
common genetic loci that are associated with PR interval. However, it is unclear whether rare and low-
frequency variants also contribute to PR interval heritability.  
Methods and Results—We performed large-scale meta-analysis of the PR interval that included 83,367 
participants of European ancestry and 9,436 of African ancestry. The Illumina HumanExome BeadChip 
examined both common and rare variants.  We identified 31 genetic loci that were significantly 
associated with PR interval after Bonferroni correction (P<1.2x10-6), including 11 novel loci that have not 
been reported previously. Many of these loci are involved in heart morphogenesis. In gene-based 
analysis, we found that multiple rare variants at MYH6 (P = 5.9x10-11) and SCN5A (P=1.1x10-7) were 
associated with PR interval. SCN5A locus also was implicated in the common variant analysis, whereas 
MYH6 was a novel locus. 
Conclusion—We identified common variants at 11 novel loci and rare variants within two gene regions 
that were significantly associated with PR interval. Our findings provide novel insights to the current 
understanding of atrioventricular conduction, which is critical for cardiac activity and an important 
determinant of health.  
 
Key Words: Electrocardiogram  PR interval  genetics  exome chip  epidemiology 
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Introduction 
Electrical conduction from the cardiac sinoatrial node to the ventricles is critical for normal heart 
function. Abnormalities of atrioventricular conduction can cause significant morbidity, and have been 
associated with atrial fibrillation (AF),1,2 need for pacemaker implantation,2 cardiac malformations, and 
sudden death.3,4 Conduction from the sinus node through the atria, atrioventricular node, and His-
Purkinje fibers is readily evaluated from surface electrocardiogram (ECG), by measurement of the 
duration of PR interval. Despite the critical role that the cardiac conduction system plays in cardiac 
physiology and disease, the formation and regulation of the conduction system remains incompletely 
understood.  
Recent data indicate that cardiac conduction measurements are heritable5-7 and have a genetic 
basis.8-11 To date, genetic studies of PR interval have been relatively modest-sized largely European-
ancestry samples, and have implicated cardiac expressed ion channels, cardiac developmental 
transcription factors, signaling molecules, as well as novel pathways not previously known to be involved 
in cardiac conduction processes. Nevertheless, existing studies have focused on the role of common and 
predominantly noncoding genetic variants, which account for only a modest proportion of trait 
heritability.6  
To better understand the biological and potential clinical implications of genetic variation underlying 
cardiac conduction, there is a need to examine both common and rare variation underlying 
atrioventricular conduction in large, well-powered, multiethnic studies. Moreover, assessment of 
genetic variation that alters protein coding has the potential to more directly implicate genes involved in 
processes critical to cardiac conduction. We therefore sought to examine PR interval duration in relation 
to predominantly coding genetic variants, in large, multi-ethnic analyses using the exome chip. 
Methods 
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The data, analytic methods, and study materials will be made available to other researchers for 
purposes of reproducing the results, subject to Data Use/Sharing Agreements adopted by individual 
participating cohorts. The summary results from the current manuscript are available at the Broad 
Cardiovascular Disease Knowledge Portal (www.broadcvdi.org). 
 
Study participants 
The current project included participants of European ancestry (EA) from 22 studies: Age, 
Gene/Environment Susceptibility Study (AGES); Atherosclerosis Risk in Communities study (ARIC); British 
Genetics of Hypertension (BRIGHT); Massachusetts General Hospital Cardiology and Metabolic Patient 
cohort (CAMP); Cardiovascular Health Study (CHS); Erasmus Rucphen Family Study (ERF); Framingham 
Heart Study (FHS); Genes for Cerebral Hemorrhage on Anticoagulation (GOCHA); Genetic Regulation of 
Arterial Pressure In Humans in the Community (GRAPHIC); INTER99; Cooperative Health Research in the 
Region Augsburg (KORA); CROATIA-Korcula (KORCULA); LifeLines Cohort Study (LifeLines); Multi-Ethnic 
Study of Atherosclerosis (MESA); The Netherlands Epidemiology of Obesity (NEO); Rotterdam Study (RS); 
Generation Scotland: Scottish Family Health Study (GS:SFHS); Study of Health in Pomerania (SHIP); 
TwinsUK; Utrecht Health Project (UHP); Women's Health Initiative (WHI); and Young Finns Study (YFS).  
In addition, we included participants of African ancestry (AA) from five studies. These studies 
included ARIC, CHS, Jackson Heart Study (JHS), MESA and WHI.  
Institutional Review Boards or Ethics Committees approved study procedures at each contributing 
site. All participants provided written informed consent to participate in genetic research.  
 
Measurement of PR interval  
PR interval duration, in milliseconds, was measured from the onset of the P wave to the onset of the 
QRS interval for each cohort. The following exclusions were applied: extreme PR values (≤ 80 ms or ≥ 
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320 ms); second or third degree heart block; atrial fibrillation on baseline ECG; history of myocardial 
infarction, heart failure, or Wolff–Parkinson–White syndrome; pacemaker placement; use of class I or III 
blocking medications (ATC code prefix C01B); digoxin use (ATC code C01AA05) or pregnancy.  
 
Genotyping  
Genotyping was performed independently in each study using the Illumina Human Exome BeadChip 
(v1.0, 1.1, or 1.2). Data were called and cleaned according to CHARGE ExomeChip best practices.12 
Detailed information for each study regarding genotyping platforms, variant calling, and quality control 
metrics is shown in Supplementary Table 1. All studies used the same set of reference alleles to recode 
variants to ensure consistency.  
 
Statistical analyses  
Prior to association analysis, PR interval was first adjusted for covariates by taking residuals from a linear 
regression of PR on age, sex, height, body mass index, and RR interval. Each cohort additionally adjusted 
as necessary for cohort-specific variables, such as clinic sites, family structure, and population structure. 
To reduce sensitivity to extreme PR values, the residuals were inverse-normal transformed and used as 
the outcome for association testing.  
Because single-marker based analyses typically have low power to identify associations between 
rare variants and traits, we separated the analysis for common and rare variants based on minor allele 
frequency (MAF). Common variants were defined as those with MAF≥1%, and the remaining variants 
were defined as rare variants (MAF<1%). For each of the common variants, we evaluated its association 
with the transformed PR interval, and accounted for multiple testing by Bonferroni correction (P < 
0.05/42075=1.2x10-6). For the rare variants, we restricted analyses to nonsynonymous or splicing 
variants with MAF <1%, because such variants are more likely to be functional than synonymous or 
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more common variants. As we expect some rare variants may act in the same or opposite directions 
even in the same gene region,13 we used a modified version of the Sequence Kernel Association Test 
(SKAT),14 which avoids problems of signals cancelling out each other in burden test results. Many gene 
regions had few or no rare nonsynonymous or splicing variants. Monomorphic variants from each study 
also were reported in the cohort level results as they were used for the cumulative MAF computations in 
gene-based tests. Gene regions with a cumulative MAF of rare variants <1% were excluded, resulting in 
5,761 gene regions that were tested (see results below). Therefore, Bonferroni-corrected significance 
threshold for our gene-based tests was P<0.05/5,761=8.7x10-6. In secondary analyses, we limited the 
analysis to damaging variants, defined as nonsense variants or variants predicted to be damaging by 
PolyPhen-2 15 or SIFT.16 
Analyses were performed using the “prepScores” function of the “seqMeta” R package. Family-
based studies implemented the “kins” option in “prepScores” to specify kinship matrices. Each study 
provided single variant z-statistics from score tests, as well as genotype covariance matrices, which were 
then combined by fixed effects meta-analysis. The heterogeneity across studies was assessed by the 
Cochran’s Q, which is a non-parametric statistical test defined as the weighted sum of squared 
differences between individual study effects and the pooled effect. We performed both race stratified 
and race combined meta-analyses, and the race combined results were used for the remaining sections 
unless stated otherwise.  
 
Comparison with genetic loci associated with AF and P-wave indices (PWI)  
We also compared genetic loci associated with PR interval with those associated with AF and PWI to see 
if there are any shared genetic mechanisms. “AF loci” were identified by a recent exome chip analysis 
that included 22,806 AF cases and 132,612 referents.17 “PWI loci” were identified from a meta-analysis 
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of P-wave duration and P-wave terminal force that included 44,456 participants.18 In addition, for each 
of the top variants associated with PR, we also examined its association with AF and PWI. 
 
Examine potential function of PR-related variants for gene expression, regulation and biological 
pathways 
Pathway analysis was performed by MAGENTA19 with default settings. The summary result for the 
common variants was used as the input, and significant pathways were defined as those with a false 
discovery rate (FDR)20  <0.05. The implication of genetic variants on cardiac gene expression (eQTL 
analysis) was performed by querying the GTEx database.21 At each PR-related locus, we identified the 
top variant and its neighboring variants that were within 500kb and in linkage disequilibrium with the 
top variant (r2 ≥ 0.5). Four heart and vascular tissues were queried, including artery aorta, artery 
coronary, atrial appendage and heart left ventricle. Significant eQTLs were defined as those with 
FDR<0.05. Regulatory regions were downloaded from the ENCODE Project22 and the NIH Roadmap 
Epigenomics Program.23 Four tracks were created: 1) included all 98 cell types from Roadmap 
epigenomics H3K27ac sites; 2) included only four heart tissues (aorta, right atrium, left ventricle, right 
ventricle) from Roadmap epigenomics H3K27ac sites; 3) included all 125 cell lines from ENCODE 
DNaseHS sites; 4) included only three heart-derived cell lines (cardiac fibroblasts, atrial fibroblasts, 
cardiac myocytes).  The enrichment of PR-related loci in regulatory regions was examined by the “VSE” R 
package.24 For comparison, we randomly created 1,000 variant sets with MAF values and LD structures 
similar to those seen for PR-related loci.  
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Results 
The current analyses included a total of 92,803 individuals from 27 cohorts, with 83,367 individuals from 
22 studies of European ancestry and 9,436 individuals from 5 studies of African ancestry. Clinical 
characteristics of the study participants are in Table 1.  
 
Identification of 31 loci associated with PR interval 
A total of 42,075 common variants were analyzed (MAF ≥ 1%). As shown in Figure 1 and Table 2, 31 loci 
were significantly associated with PR interval after Bonferroni correction (P < 1.2x10-6), including 22 loci 
that reached the conventional genome-wide significance threshold (P < 5x10-8). The results of the 
random effects meta-analysis were similar to those of the fixed effects analysis (Supplementary Table 2). 
The most significant locus was tagged by rs6795970 (P= 4.0x10-240), a missense variant in SCN10A, which 
encodes a sodium channel that has been associated previously with the PR interval (r2=0.97 with the top 
SNP rs6599250 reported previously).8 Highly associated variants clustered in the linker region between 
the second and third domains of SCN10A (Figure 2). The top variants at 12 loci are missense variants. In 
addition, the top variants at 4 loci (including 3 novel loci) are low-frequency variants (1% < MAF < 5%), 
illustrating the power of exome chip analyses to identify low-frequency coding associations. Detailed 
information of the nearest gene to each genome wide significant locus is given in Supplementary Table 
3. 
We then examined the associations between these top PR variants with AF and electrocardiographic 
PWI. Eight out of 31 PR loci identified in our analysis were associated with AF after Bonferroni correction 
(P<0.05/31=1.6x10-3), consistent with some shared mechanisms between the regulation of PR interval 
and AF. Variants in SCN10A most significantly associated with PR interval were also significantly 
associated with AF (Supplementary Table 4). Among PR-related SNPs, rs60632610 at the SYNPO2L locus 
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was most significantly associated with AF (Odds ratio: 1.90 (0.87-0.93), P=1.5x10-10). Supplementary 
Figure 1 shows the overlap among loci associated with PR interval, AF, and PWI. 
We also performed a sensitivity analysis that separated samples of European and African ancestry. 
As shown in Supplementary Table 5 and Supplementary Figure 2, all of the 31 loci except rs17391905 at 
the 1p32.3 locus (P = 2.6x10-6) were also significant in the analysis of European-only samples. 
Supplementary Table 6 and Supplementary Figure 3 show the result for the analysis of African ancestry-
only samples. Three loci were significant: SCN5A (rs3922844), SCN10A (rs6795970), and TBX5 (rs883079) 
after Bonferroni correction; P < 1.3 x 10-6. All three loci were also significant in the analysis of European-
only samples. The result from each individual study is shown in Supplementary Table 7. 
  
Rare variations in MYH6 and SCN5A are associated with PR interval  
We next examined the association between PR interval and rare variants (MAF<1%) in gene regions. 
Variation in two gene regions, MYH6 (P = 5.9x10-11) and SCN5A (P = 1.1x10-7), was associated with PR 
interval (Table 3). Supplementary Tables 8 and 9 show the association of each rare variant within MYH6 
and SCN5A with PR interval, respectively. MYH6 encodes a cardiac myosin heavy chain subunit, and 
SCN5A encodes the major cardiac sodium channel and was previously found to be associated with PR 
interval.8 MYH6 was also recently found to associate with PWI.18 We also performed an ancestry-
stratified analysis in the same way as the combined analysis. The same two gene regions were significant 
using data from European samples alone (P = 4.1x10-12 and 8.3x10-7 for MYH6 and SCN5A, respectively). 
These two genes did not reach the significance cutoff in African samples (P = 0.03 and 0.01 for MYH6 
and SCN5A, respectively). Two other genes, HEATR2 (P = 2.2x10-6) and THRAP3 (P = 4.2x10-6), were 
significantly associated in African samples alone. However, in the combined analysis, these two genes 
were not significant (P=0.02 and 0.06 for HEATR2 and THRAP3, respectively), probably due to a low 
cumulative allele frequency.   
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In our secondary analysis of pooled samples, we analyzed only damaging variants, defined as 
nonsense mutations or alternations predicted to be damaging by PolyPhen-215 or SIFT.16 Three genes 
reached the signifiance cutoff (P<0.05/2030=2.5x10-5), including GORASP1 (P=1.1x10-5), NEBL (P=1.9x10-
5), and SCN5A (P=2.2x10-5) (Supplementary Table 10).  
 
Expression quantitative trait loci (eQTL) analysis  
We also performed eQTL analysis to determine if any of the novel PR-related variants were associated 
with cardiac gene expression using data from GTEx.21 Eight loci were associated with expression of at 
least one gene in the atrial appendage, left ventricle, coronary artery, or aorta, suggesting the 
importance of these loci in the regulation of gene expression in heart or vascular tissues 
(Supplementary Table 11).   
 
Enrichment of PR-related variants in regulatory regions 
We examined involvement of PR-related variants in regulatory function. As shown in Supplementary 
Figure 4, PR-related variants were significantly enriched in regulatory regions in both primary heart 
tissues (Padj=3.7x10-9) and heart-derived cell lines (Padj=0.002), but not in all tissues (Padj>0.05). The 
observed enrichment suggested involvement of these loci in tissue-specific regulatory functions. In 
addition, the variants also tended to locate within evolutionarily conserved regions (Padj=2.8x10-5 for 
primates and 6.4x10-5 for mammals). 
 
Enrichment of PR-related variants in biological pathways   
We examined the enrichment of PR-related variants in biological pathways by MAGENTA.19 
Supplementary Table 12 shows the top pathways identified. The most significant pathway was heart 
morphogenesis (P=3.6x10-5, FDR=0.049), suggesting that many PR-related genes might be involved in 
 Page 16 of 29 
cardiac development. The pathway was only the significant pathway after correction for multiple testing 
(FDR<0.05). 
 
Discussion 
We conducted a large-scale analysis of the genetic determinants of atrioventricular conduction in 92 803 
individuals by studying the electrocardiographic PR interval. In total, we observed 31 genetic loci that 
were associated with atrioventricular conduction, 11 of which are novel. In aggregate, the results 
implicate loci containing genes encoding ion channels in the heart, sarcomeric proteins, cardiac 
transcription factors, and other proteins with unknown cardiac function. Our findings provide new 
insights to the current understanding of atrioventricular conduction, which is critical for cardiac function.  
Interestingly, rare variants in SCN5A and MYH6 were associated with PR interval. A missense 
mutation (D1275N) in SCN5A has previously been reported in a large family with multiple members 
affected by dilated cardiomyopathy, conduction disorder, and arrhythmia.25 The mutation, together 
several other mutations within the same gene, has also been associated with dilated cardiomyopathy,26 
atrial fibrillation,27 and long-QT syndrome.28-31 Rare mutations within MYH6 were associated with sick 
sinus syndrome,28 congenital heart defects,32 and atrial septal defects.33 
Our observations support and extend prior analyses of cardiac conduction. Most previous genome-
wide association studies involved the study of common genetic variation in smaller samples of up to 
28,517 individuals.8,10,11 In keeping with those prior studies, we again observed that SCN10A is the most 
prominent gene involved in atrioventricular conduction. Our recent GWAS based on 105K samples 
corroborates many of our current findings.34  However, our current study had greater power than those 
earlier analyses for assessment of rare coding variation.  
Our study has two major implications. First, our results underscore the utility of assessing coding 
variation as an efficient way to identify functional molecular domains. In particular, our findings provide 
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insights into the functional topology of SCN10A. The SCN10A sodium channel gene is widely expressed in 
the nervous system and heart,21 but it has only recently been implicated in cardiac conduction8,34-36 and 
arrhythmias such as AF35 and Brugada syndrome.37 SCN10A encodes an alpha subunit (with six 
transmembrane spanning regions), which forms tetrameric, voltage gated sodium channels responsible 
for the Nav 1.8 late sodium channel current.38,39 We found a collection of amino acid substitutions in the 
linker region between the second and third domains of SCN10A that were associated with PR duration 
(Figure 2). Variants in this linker region that were associated with the PR interval also were associated 
with AF, suggesting that function of this domain may have important clinical implications. 
Prior work on the homologous SCN5A cardiac sodium channel gene -- which is also a cardiac 
conduction locus -- indicates that this linker region is critical for sodium channel inactivation. Sodium 
influx is predominantly responsible for cardiomyocyte depolarization. Moreover, channel inactivation is 
essential for restoration of the hyperpolarized state needed for cyclic cardiomyocyte depolarization and 
contraction. Therefore, variations in this linker region might be involved in Nav 1.8 inactivation. Other 
data are necessary to identify relationships among variation in the linker region, the late sodium channel 
current, and channel inactivation in both healthy and diseased states.  
Together with previously discovered susceptibility genes, our findings implicate genes in different 
functional classes that regulate atrioventricular conduction such as ion channels and cardiac 
transcription factors. In many cases, anomalies in these genes have been found to cause human cardiac 
diseases, such as congenital heart defects, primary cardiac conduction abnormalities, and syndromes 
predisposing to sudden cardiac death (Supplementary Table 3). Interestingly, some of the genes are not 
expressed (in high abundance) in the right atrial appendage or the left ventricle, according to existing 
data sets -- although most are active in the heart (Supplementary Table 13). Atrioventricular nodal 
conduction also can be influenced by external tone from the autonomic nervous system. Therefore, 
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further work is necessary to determine the mechanisms by which identified genes that are not 
expressed in the heart influence the PR interval.  
We acknowledge several limitations of our study. Because PR interval was measured across many 
cohorts, it is possible that there is some heterogeneity that would diminish our power to detect modest 
associations. We excluded individuals with extreme values of PR interval, which might have been 
gleaned from large variations in cardiac conduction. We also performed inverse normal transformation 
on the raw PR interval to reduce the heterogeneity, which on the other hand might reduce the 
interpretability. Although we performed single-variant and gene-based tests, we did not examine the 
association of haplotype patterns with PR interval, so it is unclear if there are any haplotypes that might 
be associated with PR interval. Most of the genetic variants analyzed were in exons. Therefore the 
effects of variants within regulatory regions were not investigated. We note that the variants identified 
may not be causally related to the studied phenotypes (PR interval, AF, and PWI), but may be in LD with 
causal variants. We anticipate that future increases in sample size with additional replications and more 
comprehensive genotyping platforms, such as denser SNP arrays or genome sequencing, will help 
address these limitations.  
In conclusion, we studied genetic variants associated with PR interval duration and identified 31 
common loci -- including 11 that were novel -- and two rare variant regions. Our findings greatly expand 
our knowledge of the genes that underlie atrioventricular conduction in the heart.  
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Table 1. Clinical characteristics of the participating studies  
Ancestry Study Total N Men, N (%) Age, yrs, mean 
PR interval, 
ms, mean± 
SD 
RR interval, 
ms, mean± 
SD 
BMI, 
kg/m2, 
mean ± SD 
Height, 
cm, mean 
± SD 
SBP, 
mmHg, 
mean ± SD 
Beta 
blockers (%) 
Diuretics 
(%) 
Calcium 
antagonists* 
(%) 
European 
ancestry 
AGES 2052 742 (36.2) 75.9±5.4 170.5±26.8 895±129 27.0±4.4 166±9 143±20 635 (31.0) ND 108 (5.3) 
ARIC 9828 4528 (46.1) 54.1±5.7 160.3±23.3 928±136 26.9±4.7 169±9 118±17 789 (8.0) 1085 (11.0) 176 (1.8) 
BRIGHT 841 324 (38.9) 57.6±10.7 161.1±19.9 960±169 27.5±3.8 166±9 153±24 248 (29.5) 260 (30.9) 18 (2.1) 
CAMP 2493 1394 (55.9) 60.7±11.6 163.0±26.8 926±166 28.5±5.8 171±10 ND Excluded ND Excluded 
CHS 3247 1313 (40.4) 72.4±5.4 167.8±28.2 956±151 26.4± 4.4 165±9 136±21 366  (11.3 ) 750 (23.1) 206 (6.3 ) 
ERF 982 447 (45.5) 48.2±14.3 152.9±23.2 982±159 26.9±4.6 168±10 140±20 3 (0.3) 133 (13.5) 25 (2.5) 
FHS 7580 3428 (45.2) 39.3±9.8 152.0±22.1 910±175 26.0±5.0 169±10 119±15 Excluded ND Excluded 
GOCHA 355 161 (45.4) 73.2±8.2 167.6±27.7 913±173 26.1±4.6 169±10 N/A Excluded ND ND 
GRAPHIC 1755 893 (50.9)  39.1±14.5 153.0±24.0 934±145 26.1±4.6 171±9 128±19 39 (2.2) ND ND 
INTER99 5836 2843 (48.7) 46.1±7.9 158.2±22.4 921±150 26.3±4.6 172±9 130±18 ND ND ND 
KORA 2617 1247 (47.6) 48.3±13.0 162.1±22.2 944±149 26.9±4.4 168±9 127±19 199 (7.6) 152 (5.8) 13 (0.5) 
KORCULA 293 106 (36.2) 55.0±13.4 159.8± 24.0 929±127 28.0± 4.3 168± 9 139± 14 8 (2.7) 3 (1.0)  6 (2.0) 
LifeLines 1934 781 (40.3) 45.2±13.1 156.7±24.7 896±145 25.9±4.5 175±9 122±16 64 (3.3) 39 (2.0) 23 (1.2) 
MESA 2455 1171 (47.7) 62.8±10.2 164.7±25.2 1047±158 27.8±5.1 169±10 123±21 Excluded ND Excluded 
NEO 5782 2717 (47.0) 55.9±5.9 164.5±23.4 940±151 30.0±4.8 174±10 133±17 Excluded ND ND 
RS 2358 1086 (46.1) 68.6±8.1 168.2±24.7 871±144 26.3±3.6 168± 9 ND 293 (12.4) ND ND 
GS:SFHS 9168 3786 (41.3) 52.0±13.6 164.1± 24.9 886±146 26.9± 5.1 168± 10 134± 18 192 (2.1) ND ND 
SHIP 6493 2608 (40.2) 49.2±15.3 158.5±23.3 897±146 27.5±5.0 170±9 131±20 ND ND ND 
TwinsUK 465 32 (6.9) 52.3±11.7 159.6±22.6 923±148 26.8±5.4 163±7 119±16 ND ND ND 
UHP 1735 779 (44.9) 39.1±13.0 155.9±22.5 950±151 24.9±3.9 175±10 125±17 69 (4.6) 32 (1.8) 18 (1.0) 
WHI 13252 0 (0) 66.0±6.5 161.4±24.0 921±138 28.7±5.6 162±6 130±18 735 (5.5) 1715 (13.3) 1230 (9.3) 
YFS 1846 824 (44.6) 41.9±5.0 156.2±22.6 1028±165 26.4±4.9 172±9 119±14 38 (2.1) 24 (1.3) 1 (0.1) 
African 
ancestry 
ARIC 3366 1291 (38.4) 53.3±5.8 171.2±26.8 929±151 29.4±6.1 168±9 128±22 315 (9.4) 717 (21.3) 222 (6.6) 
CHS 627 232  (37.0 ) 72.4±5.5 170.2±28.1 918±161 28.4± 5.5 165±9 142± 22 54 (8.6) 217 (34.6) 60 (9.6 ) 
JHS 2220 833 (37.5) 52.7±12.5 172.7±27.3 956±150 31.4±6.4 169±9 126±18 Excluded ND Excluded 
MESA 1565 718 (45.9) 62.3±10.0 170.9±26.3 1050±172 30.2±5.9 168±10 132±21 Excluded ND Excluded 
WHI 1658 0 (0) 64.6±6.4 167.1± 24.8 921±148 31.1±5.8 162±7 134±17 87 (5.2) 393 (23.7) 341 (20.6) 
Exclusion criteria are given in Supplementary Table 1. SBP, systolic blood pressure; BMI, body mass index; ND, not determined; SD, standard deviation; *Non-
dihydropyridine calcium antagonists. 
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Table 2. Common variants significantly associated with PR interval from meta-analysis of all studies 
SNP Locus Closest gene Function 
Coding 
allele CAF* Beta SE P value 
Number 
of 
studies‡ 
Prolong 
or 
shorten 
PR 
interval  
Novel 
locus 
rs6795970 3p22.2 SCN10A Missense A 0.37 0.1705 0.0052 4.0x10-240 27 Prolong  
rs3922844 3p22.2 SCN5A Intronic A 0.34 -0.1069 0.0053 9.3x10-90 26 Shorten  
rs3807989 7q31.2 CAV1 Intronic A 0.43 0.0908 0.0050 3.0x10-74 27 Prolong  
rs7660702 4q21.23 ARHGAP24 Intronic C 0.33 -0.0921 0.0053 1.2x10-68 27 Shorten  
rs17287293 12p12.1 LINC00477 Intergenic G 0.14 -0.1084 0.0071 1.9x10-52 27 Shorten  
rs11897119 2p14 MEIS1 Intronic C 0.39 0.0566 0.0055 4.2x10-25 25 Prolong  
rs1896312 12q24.21 TBX3 Intergenic G 0.28 0.0564 0.0055 8.7x10-25 26 Prolong  
rs883079 12q24.21 TBX5 3'UTR G 0.29 0.0550 0.0054 4.5x10-24 26 Prolong  
rs116202356 3p22.2 DLEC1 Missense A 0.02 -0.1953 0.0199 1.0x10-22 27 Shorten  
rs251253 5q35.1 CREBRF Intergenic G 0.42 -0.0439 0.0051 4.7x10-18 26 Shorten  
rs11153730 6q22.31 SLC35F1 Intergenic C 0.47 -0.0420 0.0049 9.5x10-18 27 Shorten Novel 
rs35658696 5q21.1 PAM Missense G 0.04 0.0956 0.0119 8.5x10-16 27 Prolong  
rs2070492 3p22.2 SLC22A14 Missense T 0.10 0.0624 0.0083 4.0x10-14 27 Prolong Novel 
rs2585897 13q12.11 XPO4 Intronic A 0.17 0.0471 0.0064 2.8x10-13 27 Prolong  
rs2042995 2q31.2 TTN Missense C 0.26 0.0375 0.0057 4.3x10-11 27 Prolong  
rs4399693 2p25.1 ID2 Intergenic A 0.34 0.0374 0.0058 9.1x10-11 25 Prolong  
rs41306688 13q34 ADPRHL1 Missense C 0.03 0.1002 0.0173 7.4x10-9 22 Prolong Novel 
rs4745 1q22 EFNA1 Missense T 0.49 0.0299 0.0053 1.2x10-8 26 Prolong  
rs11078078 17p12 LINC00670 Intronic A 0.40 0.0281 0.0050 2.2x10-8 27 Prolong  
rs60632610 10q22.2 SYNPO2L Missense T 0.15 -0.0371 0.0068 4.5x10-8 27 Shorten Novel 
rs11848785 14q24.2 SIPA1L1 Intronic G 0.24 0.0317 0.0058 4.6x10-8 27 Prolong  
rs3733414 4q35.2 FAT1 Missense A 0.38 0.0280 0.0051 4.8x10-8 27 Prolong  
rs17362588 2q31.2 CCDC141 Missense A 0.08 -0.0491 0.0090 5.5x10-8 27 Shorten Novel 
rs2296172 1p34.3 MACF1 Missense G 0.20 0.0326 0.0061 1.1x10-7 27 Prolong Novel 
rs9398652 6q22.31 GJA1 Intergenic A 0.14 0.0390 0.0074 1.3x10-7 26 Prolong Novel 
rs442177 4q22.1 AFF1 Intronic C 0.42 -0.0262 0.0050 1.8x10-7 26 Shorten Novel 
rs7002002 8q24.3 PLEC Missense A 0.38 -0.0272 0.0052 2.1x10-7 25 Shorten Novel 
rs1768208 3p22.1 MOBP Intron T 0.25 0.0288 0.0057 3.6x10-7 27 Prolong Novel 
rs2119788 4q34.1 HAND2 Intergenic C 0.52 -0.0246 0.0049 5.6x10-7 27 Shorten Novel 
rs17391905† 1p32.3 C1orf185 Intergenic G 0.03 -0.0694 0.0142 9.6x10-7 27 Shorten  
rs524295 10q24.1 ALDH18A1 Intergenic A 0.40 -0.0261 0.0053 9.7x10-7 26 Shorten  
*Coding allele frequency 
†SNP was not significant if African participants were excluded.  
‡Some variants did not reach pass the quality filtering in respective studies and thus were excluded.  
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Table 3. Top 10 gene regions associated with PR interval by the SKAT test* 
Gene P value Qmeta† CMAF‡ #Variants 
Number of 
studies with at 
leat one rare 
variant 
Average 
number of 
variants in 
each study 
MYH6 5.9x10-11 23537340 0.0215 32 27 12 
SCN5A 1.1x10-7 16604843 0.0289 35 27 13 
GORASP1 1.3x10-5 14361252 0.0308 16 27 6 
NEBL 1.9x10-5 11787699 0.0309 36 27 11 
TRIML2 1.2x10-4 10173978 0.0223 23 27 10 
SLC22A11 1.5x10-4 6539656 0.0136 11 27 6 
MTRF1 2.8x10-4 9073098 0.0235 10 26 3 
CD36 3.5x10-4 8001777 0.0156 28 27 9 
CAPRIN2 3.7x10-4 6886375 0.0169 15 27 7 
PIK3R6 6.0x10-4 9763336 0.0316 23 26 8 
*The analysis included only nonsynonymous and splice site rare variants (MAF<1%) within the gene regions  
†Qmeta: The SKAT Q-statistic, defined as ∑ 𝑤𝑗𝑆𝑗𝑛𝑗=1 , where 𝑤𝑗 is the weight, and 𝑆𝑗  is the squared score.  
‡CMAF: Cumulative minor allele frequency; SKAT: Sequence Kernel Association Test 
The significance level for gene-based tests after Bonferroni correction was P<0.05/5759=8.7x10-6; the two genes 
that reached this significant cutoff are highlighted in bold font.  
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Figure Legends 
 
Figure 1. Manhattan plot showing the association between common variants and PR interval from 
combined ancestry analysis. The x-axis represents the chromosomal position for each SNP, and the y-
axis represents the –log10(p-value) of the association with PR interval. The dashed line represents the 
genome-wide significance cutoff of 5x10-8, and the blue line represents the Bonferroni P-value cutoff of 
1.3x10-6. Black color represents known loci, whereas red color represents novel loci. 
 
 
Figure 2. Diagram of sodium voltage-gated channel alpha subunit 10 (SCN10A). Each yellow circle 
represents a genetic variant with a P-value less than the significance cutoff (1.2 x 10-6). Each red circle 
represents a genetic variant with a P-value greater than the significance cutoff, but less than 0.05.  
 
